HighTide Therapeutics Inc (HKSE:02511) Share Price

Company Profile

Business description
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Contact
Building D, Guangdong
Floor 9 to 10, Fubao Community, Futian District
Shenzhen-Hong Kong Science and
Technology Innovation Cooperation Zone
Shenzhen518112
CHN
T: +86 75526626253
https://www.hightidetx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
57

Recommended

Shares have dropped 20% in the previous year due to concerns about tariffs.

Esther Holloway | 27 October 2025

Higher gold prices are making a difference to the bottom line but investors overly optimistic.

Jon Mills, CFA | 27 October 2025

We see faster cloud growth and improved longer-term profitability for Alphabet.

Malik Ahmed Khan, CFA | 25 October 2025

Index	Last price	Change	% Change
All Ordinaries	9,306.10	15.90	-0.17%
CAC 40	8,239.18	13.55	0.16%
DAX 40	24,308.78	68.89	0.28%
Dow JONES (US)	47,544.59	337.47	0.71%
FTSE 100	9,653.82	8.20	0.09%
HKSE	26,370.20	63.50	-0.24%
NASDAQ	23,637.46	432.59	1.86%
Nikkei 225	50,263.58	248.74	-0.49%
NZX 50 Index	13,405.00	13.41	0.10%
S&P 500	6,875.16	83.47	1.23%
S&P/ASX 200	9,025.40	3.40	-0.04%
SSE Composite Index	3,990.70	6.25	-0.16%